Supernus Pharmaceuticals Inc (SUPN)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	-1	60,711	53,424	126,950	113,056
Total stockholders’ equity	US$ in thousands	1	0	815,851	744,858	595,428
ROE		-100.00%	—	6.55%	17.04%	18.99%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $-1K ÷ $1K
= -100.00%

Supernus Pharmaceuticals Inc's return on equity (ROE) has shown a declining trend over the past five years. The ROE was at 18.99% in 2019, but has gradually decreased to 17.04% in 2020, 6.55% in 2021, 6.85% in 2022, and further dropped to 0.14% in 2023. This decline in ROE indicates that the company's ability to generate profit from its shareholder's equity has been weakening over time. It is essential for Supernus Pharmaceuticals Inc to analyze the factors contributing to this decline in ROE and make strategic decisions to improve profitability and efficiency in order to enhance shareholder value.